Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jun 3, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on improving how doctors evaluate PET scans for patients with neuroendocrine tumors, a type of cancer that can be hard to treat. The researchers want to create new guidelines to help doctors better understand if a patient's cancer is getting better, worse, or staying the same after treatment. They will also compare these new guidelines to the current ones to see which is more effective. This study aims to help both patients and doctors make more informed decisions about treatment options.

To participate in this trial, individuals should have a confirmed diagnosis of metastatic or inoperable neuroendocrine tumors that have specific characteristics, including certain types of receptor activity visible on scans. Eligible participants will be those aged 65 and older, who have measurable cancer that can be tracked over time. If you join the study, you can expect to undergo PET scans and be part of a process that could lead to better treatment evaluations for neuroendocrine tumors in the future.

Gender

ALL

Eligibility criteria

• • Subjects affected by histologically proven, somatostatin-receptor positive, metastatic or inoperable well-differentiated G1, G2 or G3 neuroendocrine tumors (NETs) candidate to receive PRRT with 177Lu-DOTATATE per standard of care.
• Inclusion Criteria:
• • 1. Histologically proven or cytologically confirmed, metastatic or inoperable NETs
• • 2. Measurable disease as defined by RECIST 1.1.
• • 3. Overexpression of somatostatin receptors of the target lesions at somatostatin receptor imaging (68Ga-DOTATATE or 64Cu-DOTATATE PET/CT) with SUV of lesions greater than normal liver at least in 1 metastasis.
• Exclusion Criteria:
• • 1. Neuroendocrine Carcinoma), small and large cell type; MIxed Neuroendocrine-Nonneuroendocrine Neoplasm (MiNEN).
• • 2. Presence of somatostatin receptor negative lesions.